← Community

Fundraising · Product

What I Learned From a Founder Making Epinephrine Injectors the Size of ChapStick

Kiran Panjwani · October 8, 2026

I heard Linda Waller talk about her company Medigo today, and one thing she said stuck with me: the problem with life-threatening allergies isn't the medicine. It's that people don't carry it.

She's building an epinephrine injector called Epigo that's the size of a ChapStick tube because EpiPens are too big and inconvenient. People leave them at home. And when anaphylaxis hits, you don't have time to go home and get your medicine.

The actual insight: adoption beats perfection

Linda's not trying to make a better drug. Epinephrine works. What she's solving is the fact that a six-inch EpiPen doesn't fit in your pocket, doesn't come with you to the restaurant, and ends up in a drawer somewhere when you actually need it on your body.

Epigo is 2.5 inches long and 1 inch wide. That's the entire design challenge. Make it small enough that people actually carry it.

This is the kind of insight that seems obvious once someone says it out loud, but it took Linda to actually build a company around it. The best medical technology in the world is worthless if it's sitting at home.

She's fundraising and doing customer discovery at the same time

Linda mentioned she's currently raising a pre-seed round. And while she's doing that, she's also planning surveys to figure out what the actual biggest problem is with carrying EpiPens.

I've always thought of fundraising and customer discovery as sequential. Validate first, then raise. Or raise first, then build. But Linda's doing both in parallel, which makes sense when you think about it. She needs to show investors there's a real problem worth solving, and the best way to do that is to talk to the people who live with the problem every day.

She has early proof-of-concept prototypes already, which probably helps. It's not just a pitch deck. It's a thing you can hold.

Medical devices are nothing like software

The other thing that stood out to me: hardware timelines are brutal.

Linda talked about prototyping and R&D milestones that are tied directly to fundraising success. You can't just iterate fast and break things. Paragon Medical handles the R&D for Epigo, taking it from design through small-scale manufacturing. That's not a weekend sprint. That's months or years of work with regulatory requirements and manufacturing partners and all the friction that comes with building something physical.

Software founders can ship an MVP in a few weeks and start getting feedback. Medical device founders have to nail the design, prototype it, test it, get it manufactured, and then start thinking about regulatory approval. The timelines are completely different.

And fundraising has to account for that. Investors aren't just betting on product-market fit. They're betting on your ability to navigate a multi-year R&D process and come out the other side with something that works and is approved and can actually be sold.

What I took away

Linda's approach is a good reminder that the best startup ideas often aren't about inventing new technology. They're about removing the friction that keeps existing technology from being used.

Epinephrine already saves lives. Linda's just making sure it's actually there when people need it.

And if you're building in medtech or hardware, the rules are different. Fundraising and product development overlap in weird ways. Timelines are longer. Partnerships matter more. You can't fake it till you make it with a Figma prototype.

But the core insight still matters most. If people won't carry your product, it doesn't matter how good it is.

Written by Kiran Panjwani with Yapship.

More on Fundraising and Product